Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment.

PubWeight™: 0.94‹?›

🔗 View Article (PMC 3740406)

Published in Otolaryngol Clin North Am on June 27, 2013

Authors

Juliana Bonilla-Velez1, Edmund A Mroz, Rebecca J Hammon, James W Rocco

Author Affiliations

1: Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.

Associated clinical trials:

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer | NCT01302834

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer | NCT01084083

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients | NCT01493154

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | NCT01585428

Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer (REALISTIC:) | NCT01598792

De-intensification of Radiation and Chemotherapy for Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma | NCT01530997

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | NCT01064921

Immune Therapy of HPV-induced Cancers | NCT01462838

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer | NCT00019110

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | NCT01221753

Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | NCT01088802

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity | NCT01525927

A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR) (ORATOR) | NCT01590355

Articles cited by this

Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77

Human papillomavirus and cervical cancer. Lancet (2007) 12.47

Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46

HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53

Prevalence of oral HPV infection in the United States, 2009-2010. JAMA (2012) 6.02

High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86

EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46

Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer (2010) 4.99

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39

Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer (2007) 3.98

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70

Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res (2003) 3.42

Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol (2006) 2.91

Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer (2010) 2.69

Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol (2011) 2.47

E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst (2009) 2.45

Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res (2005) 2.32

Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer (2000) 2.17

Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health (2010) 2.14

Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol (2010) 2.02

Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol (2012) 1.96

Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg (2009) 1.80

Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64

Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol (2012) 1.63

p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck (2011) 1.62

The natural history of human papillomavirus infections of the mucosal epithelia. APMIS (2010) 1.61

Oncogenic activities of human papillomaviruses. Virus Res (2009) 1.60

Implications of the oropharyngeal cancer epidemic. J Clin Oncol (2011) 1.49

The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med (2011) 1.40

An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer (2012) 1.36

Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg (2010) 1.31

Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am (2008) 1.28

Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25

Unequal burden of head and neck cancer in the United States. Head Neck (2008) 1.22

Epidemiology of human papillomavirus-related head and neck cancer. Otolaryngol Clin North Am (2012) 1.18

HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett (2009) 1.13

COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res (2008) 1.09

Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer. Laryngoscope (2012) 1.09

Exploring biomarkers in head and neck cancer. Cancer (2012) 1.08

Human papillomavirus-related squamous cell carcinoma of the oropharynx: a comparative study in whites and African Americans. Arch Otolaryngol Head Neck Surg (2011) 1.07

Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer (1996) 1.05

Race impacts outcome in stage III/IV squamous cell carcinomas of the head and neck after concurrent chemoradiation therapy. Cancer (2009) 1.05

Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res (2010) 1.04

The emergence of endoscopic head and neck surgery. Curr Oncol Rep (2010) 1.02

The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature. ISRN Oncol (2012) 1.01

Organ-sparing radiation therapy for head and neck cancer. Nat Rev Clin Oncol (2011) 0.99

Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs (2010) 0.97

Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol (2004) 0.95

Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol (2011) 0.94

Robotic surgery for oropharynx cancer: promise, challenges, and future directions. Curr Oncol Rep (2012) 0.87

Minimally invasive techniques for head and neck malignancies: current indications, outcomes and future directions. Eur Arch Otorhinolaryngol (2011) 0.85

Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. Oral Oncol (2010) 0.85

Update on molecular diagnostic tests in head and neck cancer. Semin Oncol (2008) 0.84

Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. Eur Arch Otorhinolaryngol (2010) 0.83

Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab? Lancet Oncol (2010) 0.80

Articles by these authors

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res (2005) 1.97

Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet (2006) 1.66

Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res (2006) 1.59

HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg (2009) 1.49

Implications of the oropharyngeal cancer epidemic. J Clin Oncol (2011) 1.49

Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res (2013) 1.47

High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43

MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol (2012) 1.31

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest (2011) 1.19

Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res (2009) 1.18

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res (2010) 1.13

COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res (2008) 1.09

Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res (2010) 1.04

Free flap reconstruction in 1999 and 2009: changing case characteristics and outcomes. Laryngoscope (2012) 0.85

Short hairpin RNA system to inhibit human p16 in squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2004) 0.83

Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer (2005) 0.83

Gene expression analysis as a tool in early-stage oral cancer management. J Clin Oncol (2012) 0.83

Quantitative analysis of the effect of cell type and cellular differentiation on protective antigen binding to human target cells. FEBS Lett (2006) 0.82

Surgical salvage of the oropharynx after failure of organ-sparing therapy. Head Neck (2011) 0.80

Castleman disease presenting in the neck: report of a case and review of the literature. Am J Otolaryngol (2013) 0.80

Temporary intraoperative external fixation in mandibular reconstruction. Laryngoscope (2002) 0.80

Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer. J Clin Oncol (2010) 0.78

The time course and microbiology of surgical site infections after head and neck free flap surgery. Laryngoscope (2014) 0.76

Pathology quiz case 1. Angiosarcoma. Arch Otolaryngol Head Neck Surg (2011) 0.75

Cervical presentation of peripheral T-cell lymphoma not otherwise specified. Ear Nose Throat J (2014) 0.75

Solitary myofibroma of the oropharynx causing airway obstruction in an adult. Ear Nose Throat J (2014) 0.75

Rosai-Dorfman disease presenting in the oropharynx. Head Neck (2010) 0.75

Pathology quiz case 2. Sarcoidosis. Arch Otolaryngol Head Neck Surg (2009) 0.75

Pathology quiz case 1. Adenocarcinoma with features of mucinous adenocarcinoma (MAC) and cystadenocarcinoma (CAC). Arch Otolaryngol Head Neck Surg (2005) 0.75

Pathology quiz case 1. Diffuse large B-cell lymphoma (DLBCL) of the thyroid. Arch Otolaryngol Head Neck Surg (2011) 0.75

RNA interference: natural, experimental, and clinical roles in cancer biology. Head Neck (2006) 0.75